RecruitingPhase 2NCT06541574

Prevention of ProliFerative Vitreoretinopathy with Intravitreal MethotreXate in Primary Retinal DEtachment Repair (FIXER) Trial

Studying Vitreoretinopathy

Last synced from ClinicalTrials.gov April 1, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: Cincinnati Eye Institute, Southwest Ohio
Intervention: Methotrexate Injection(drug)
Enrollment: 860 target
Eligibility: 18 years · All sexes
Timeline: 2024 – 2026

Study locations (1)

Cincinnati Eye Institute, Cincinnati, Ohio, United States

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT06541574 on ClinicalTrials.gov

Other trials for Vitreoretinopathy

Additional recruiting or active studies for the same condition.

RECRUITINGPHASE1, PHASE2NCT06033703
Topical Netarsudil for the Prevention of Proliferative Vitreoretinopathy in Patients With Retinal Detachment
Massachusetts Eye and Ear Infirmary
RECRUITINGPHASE2NCT05523869
Intravitreal Topotecan in the Repair of Rhegmatogenous Retinal Detachment with Proliferative Vitreoretinopathy
Unity Health Toronto
ACTIVE NOT RECRUITINGPHASE2, PHASE3NCT05660447
A Multi-Center Study on the Use of Rho-Kinase Inhibitor to Reduce or Prevent PVR in RRD Eyes at High Risk for PVR
Wills Eye

See all trials for Vitreoretinopathy →

← Back to all trials